Renal Toxicity after Radionuclide Therapy
- 1 May 2004
- journal article
- review article
- Published by Radiation Research Society in Radiation Research
- Vol. 161 (5) , 607-611
- https://doi.org/10.1667/rr3105
Abstract
Lambert, B., Cybulla, M., Weiner, S. M., Van De Wiele, C., Ham, H., Dierckx, R. A. and Otte, A. Renal Toxicity after Radionuclide Therapy. Radiat. Res. 161, 607–611 (2004).During the past 10 years, a variety of radiolabeled monoclonal antibodies, antibody fragments, and low-molecular- weight oncophilic peptides have been used to deliver radioactivity to target cells for therapeutic purposes. The high and persistent localization of several of these radiolabeled molecules in the kidneys raised concern about potential renal radiation toxicity compromising therapeutic effectiveness. In particular, radiolabeled peptides, such as yttrium-90-labeled synthetic somatostatin analogues, have initiated a discussion on the safety profiles of the various somatostatin derivatives in recent clinical trials. In general, the toxicity risk seems to depend on the characteristics of the oncophilic molecule, such as the molecular weight, electric charges and clearance pathways as well as the chemical and physical characteristics of the applied radionuclide. Encouraging results for the prevention of radiation-induced renal damage by radiolabeled peptides have been obtained by co-infusion of positively charged amino acids. The available literature on nephrotoxicity after radiolabeled peptide therapy is reviewed, and therapeutic options that have become available as a result of greater insights into putative pathogenic mechanisms are discussed.Keywords
This publication has 23 references indexed in Scilit:
- Radiolabelled peptides for tumour therapy: current status and future directionsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- 111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trialSeminars in Nuclear Medicine, 2002
- Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experienceSeminars in Nuclear Medicine, 2002
- End-stage renal disease after treatment with 90 Y-DOTATOCEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinomaNephrology Dialysis Transplantation, 2001
- Radiation nephropathy after bone marrow transplantationKidney International, 2000
- Yttrium-90 DOTATOC: first clinical resultsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1999
- Tolerance of normal tissue to therapeutic irradiationPublished by Elsevier ,1991
- RADIATION NEPHRITIS: A Long-term Study of 54 PatientsThe Lancet, 1961